BERKELEY, Calif.--(BUSINESS WIRE)--Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision restoration therapies for those living with severe retinal degenerations, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to its lead program, RTx-015, for the treatment of retinitis pigmentosa (RP). PRIME (PRIority MEdicines) is awarded to therapies that have the potential to addres
2026 Copyright © News-Matic.com. All Rights Reserved
